AU3595393A - Transdermal administration of buprenorphine in the form of ion pair complexes - Google Patents

Transdermal administration of buprenorphine in the form of ion pair complexes

Info

Publication number
AU3595393A
AU3595393A AU35953/93A AU3595393A AU3595393A AU 3595393 A AU3595393 A AU 3595393A AU 35953/93 A AU35953/93 A AU 35953/93A AU 3595393 A AU3595393 A AU 3595393A AU 3595393 A AU3595393 A AU 3595393A
Authority
AU
Australia
Prior art keywords
buprenorphine
transdermal administration
ion pair
pair complexes
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35953/93A
Inventor
Chia-Ming Chiang
Gordon L. Flynn
Eric J Roos
Kuldeepak Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cygnus Therapeutic Systems
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Publication of AU3595393A publication Critical patent/AU3595393A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU35953/93A 1992-01-31 1993-01-27 Transdermal administration of buprenorphine in the form of ion pair complexes Abandoned AU3595393A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82795092A 1992-01-31 1992-01-31
US827950 1992-01-31

Publications (1)

Publication Number Publication Date
AU3595393A true AU3595393A (en) 1993-09-01

Family

ID=25250560

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35953/93A Abandoned AU3595393A (en) 1992-01-31 1993-01-27 Transdermal administration of buprenorphine in the form of ion pair complexes

Country Status (2)

Country Link
AU (1) AU3595393A (en)
WO (1) WO1993014727A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (en) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
DE10019171A1 (en) * 2000-04-07 2001-10-18 Schering Ag Compositions for use as penetration enhancers in transdermal formulations for highly lipophilic active ingredients
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (en) 2002-07-30 2007-08-16 Schwarz Pharma Ag Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS
DE10261696A1 (en) 2002-12-30 2004-07-15 Schwarz Pharma Ag Device for the transdermal administration of rotigotine base
CN110441302B (en) * 2018-05-03 2021-12-07 中国医学科学院药物研究所 Nondestructive quality control method for tulobuterol transdermal patch

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine

Also Published As

Publication number Publication date
WO1993014727A1 (en) 1993-08-05

Similar Documents

Publication Publication Date Title
AU627845B2 (en) Improvements in or relating to devices for administration of drugs or the like
EP0535111A4 (en) Transdermal administration of buprenorphine
AU3401895A (en) Spiro-azabicyclic compounds useful in therapy
AU5784994A (en) Formulation for use in smokers
AU4338289A (en) Cyclodextrin-peptide complexes
AU7237394A (en) Morphinan derivative and medicinal use
AU7122291A (en) 3-arylcarbonyl-1h-indoles useful as therapeutic agents
AU3290089A (en) Deprenyl for systemic transdermal administration
AU665287B2 (en) Prostaglandin combinations in glaucoma therapy
AU3152993A (en) Improvements in the administration of aerosol compounds
AU1907788A (en) N-aminobutyl-n-phenylarylamide derivatives, their preparation and their application in therapy
AU622779B2 (en) Keggin ion compounds in HIV treatment
AU1111388A (en) Triazinetriones as agents against protozoa in insects
AU3552189A (en) Use of metal chelate complexes in dehalogenation
AU3595393A (en) Transdermal administration of buprenorphine in the form of ion pair complexes
AU574926B2 (en) Anti-cancer treatment using imidazolyl or pyridyl alkoxyphenoxydimethylalkanoates
AU4860693A (en) Piperidine derivatives, their preparation and their application in therapy
AU1870292A (en) Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
AU7793791A (en) Pharmaceutical composition for use in treating pain
AU4060289A (en) Therapeutic agents
AU4980693A (en) Improvements in skin plasters
AU4579793A (en) Improvements in and relating to biscuits
AU627033B2 (en) 1-phenyl-1,4-dihydro-3-amino-4-oxopyridazine derivatives, their preparation and their application in therapy
AU2192783A (en) 3:,5:-diarabinosides preparation and application in therapy
AU6491890A (en) Use of arylalkylamides in the treatment of neurodegenerative diseases